GeneDx Holdings Corp. Amended Major Shareholder Report
GeneDx Holdings Corp. major shareholders Eli Casdin and Keith Meister have filed Amendment No. 10 to their Schedule 13D, updating their ownership and derivative positions in the company’s Class A common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
GeneDx Holdings Corp. major shareholders Eli Casdin and Keith Meister have filed Amendment No. 10 to their Schedule 13D, updating their ownership and derivative positions in the company’s Class A common stock.
Based on 29,688,027 Shares outstanding as of May 1, 2026, Keith Meister is reported to beneficially own 5,005,494 Shares, representing 16.7% of the class, primarily through investment funds advised by Corvex Management LP and interests in CMLS Holdings LLC. Eli Casdin is reported to beneficially own 3,599,671 Shares, or 12.0% of the class, through Casdin-affiliated funds, CMLS Holdings LLC, and equity awards tied to his board service.
The amendment also describes cash-settled swaps entered into by Casdin Partners Master Fund, LP with Morgan Stanley, providing economic long exposure equivalent to a notional 850,000 Shares in total. These swaps are cash-settled only, confer no voting or dispositive power over GeneDx securities, and are expressly disclaimed as beneficial ownership.
Insights
Amended 13D refines large holders’ stakes and adds swap exposure.
The amendment details how funds associated with Eli Casdin and Keith Meister collectively hold sizable positions in GeneDx Holdings Corp. Common stock ownership is broken down by entity, with beneficial ownership percentages calculated against 29,688,027 Shares outstanding as of May 1, 2026.
The filing also outlines three cash-settled swaps between Casdin Partners Master Fund, LP and Morgan Stanley referencing an aggregate notional 850,000 Shares, with cost bases between $38.1543 and $41.0261 per Share and termination dates in June 2029. These instruments provide economic exposure but no voting or dispositive rights, and beneficial ownership of the referenced Shares is expressly disclaimed.
Overall, this looks like a detailed position update rather than a transformative event. Future GeneDx filings may clarify any further changes in equity or derivative exposure if these holders adjust their strategies or unwind derivatives near their 2029 termination dates.
Key Figures
Key Terms
beneficial ownership financial
cash-settled swaps financial
margin accounts financial
private placement warrants financial
restricted stock units financial
notional interest financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of GeneDx (WGS) does Keith Meister beneficially own in this Schedule 13D/A?
How much GeneDx (WGS) stock does Eli Casdin beneficially own according to the amended 13D?
What cash-settled swaps linked to GeneDx (WGS) are disclosed for Casdin Partners Master Fund, LP?
Do the disclosed swaps give Casdin Partners Master Fund, LP voting power over GeneDx (WGS) shares?
What private placement warrants tied to GeneDx (WGS) are included in Casdin and Meister’s beneficial ownership?
AI-generated analysis. How Rhea-AI works. Not financial advice.